IN2014MN02467A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02467A
IN2014MN02467A IN2467MUN2014A IN2014MN02467A IN 2014MN02467 A IN2014MN02467 A IN 2014MN02467A IN 2467MUN2014 A IN2467MUN2014 A IN 2467MUN2014A IN 2014MN02467 A IN2014MN02467 A IN 2014MN02467A
Authority
IN
India
Prior art keywords
tetrahydrothieno
thiazol
dioxo
pyrimidin
difluoro
Prior art date
Application number
Other languages
English (en)
Inventor
Suresh Mahadev Kadam
Abraham Thomas
Sukumar Sinha
Sukeerthi Kumar
Bipin Parsottam Kansagra
Sachin Gavhane
Sandeep Bandu Khandagale
Shailesh Pawase
Jayant Prakashrao Patil
Shailendra Bhadane
Bhavna Mishra
Rajesh Dwivedi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN02467(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Priority to IN2467MUN2014 priority Critical patent/IN2014MN02467A/en
Publication of IN2014MN02467A publication Critical patent/IN2014MN02467A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN2467MUN2014 2012-06-08 2013-06-08 IN2014MN02467A (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2467MUN2014 IN2014MN02467A (da) 2012-06-08 2013-06-08

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1687MU2012 2012-06-08
US201261665282P 2012-06-27 2012-06-27
IN3519MU2012 2012-12-13
US201261748016P 2012-12-31 2012-12-31
IN2467MUN2014 IN2014MN02467A (da) 2012-06-08 2013-06-08
PCT/IB2013/054703 WO2013183035A2 (en) 2012-06-08 2013-06-08 Amides of 2-amino-4-arylthiazole compounds and their salts

Publications (1)

Publication Number Publication Date
IN2014MN02467A true IN2014MN02467A (da) 2015-07-10

Family

ID=54193746

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2467MUN2014 IN2014MN02467A (da) 2012-06-08 2013-06-08

Country Status (22)

Country Link
US (1) US9458173B2 (da)
EP (1) EP2858999B1 (da)
JP (1) JP5989900B2 (da)
KR (1) KR20150015488A (da)
CN (1) CN104350058A (da)
AP (1) AP3546A (da)
AU (1) AU2013273118B2 (da)
BR (1) BR112014029155A2 (da)
CA (1) CA2873570C (da)
CL (1) CL2014003317A1 (da)
EA (1) EA031334B1 (da)
HK (1) HK1207643A1 (da)
IL (1) IL236084A0 (da)
IN (1) IN2014MN02467A (da)
MX (1) MX354014B (da)
MY (1) MY165622A (da)
NZ (1) NZ701721A (da)
PE (1) PE20142306A1 (da)
PH (1) PH12014502685B1 (da)
SG (1) SG11201408093PA (da)
WO (1) WO2013183035A2 (da)
ZA (1) ZA201500082B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150040265A (ko) 2012-06-08 2015-04-14 길리애드 사이언시즈, 인코포레이티드 플라비비리대 바이러스의 마크로시클릭 저해제
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
BR112015030341A2 (pt) 2013-06-20 2017-07-25 Glenmark Pharmaceuticals Sa formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
WO2016023832A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
US20190175599A1 (en) * 2014-09-16 2019-06-13 Glemark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
TW202321229A (zh) 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
CA2536313A1 (en) * 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
JPWO2006083005A1 (ja) 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
CA2617788A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
US20070105920A1 (en) 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
TW201900217A (zh) 2005-12-22 2019-01-01 美商海卓勒生物科學公司 用於調節trpa1功能之化合物
CN101454318A (zh) * 2006-03-22 2009-06-10 阿斯利康(瑞典)有限公司 吡啶并嘧啶衍生物及其作为pde4抑制剂的用途
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
JP2011201776A (ja) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−n−(3,4−ジヒドロ−2(1h)−キナゾリノン−5−イル)アセトアミド誘導体
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
CN101801362B (zh) 2007-06-22 2014-01-22 海德拉生物科学公司 用于治疗病症的方法和组合物
WO2010004390A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
SG174403A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists

Also Published As

Publication number Publication date
MY165622A (en) 2018-04-18
ZA201500082B (en) 2015-12-23
AP3546A (en) 2016-01-14
PE20142306A1 (es) 2015-01-16
IL236084A0 (en) 2015-02-01
PH12014502685A1 (en) 2015-01-26
AP2014008076A0 (en) 2014-11-30
BR112014029155A2 (pt) 2017-06-27
JP5989900B2 (ja) 2016-09-07
EA201492054A1 (ru) 2016-08-31
NZ701721A (en) 2016-03-31
PH12014502685B1 (en) 2015-01-26
US20150111038A1 (en) 2015-04-23
KR20150015488A (ko) 2015-02-10
CA2873570C (en) 2016-11-01
MX354014B (es) 2018-02-08
WO2013183035A3 (en) 2014-02-27
CL2014003317A1 (es) 2015-02-13
HK1207643A1 (en) 2016-02-05
SG11201408093PA (en) 2015-01-29
EP2858999A2 (en) 2015-04-15
EP2858999B1 (en) 2017-05-10
JP2015520183A (ja) 2015-07-16
AU2013273118B2 (en) 2015-11-05
AU2013273118A1 (en) 2014-11-27
US9458173B2 (en) 2016-10-04
WO2013183035A2 (en) 2013-12-12
MX2014014482A (es) 2015-06-05
CN104350058A (zh) 2015-02-11
CA2873570A1 (en) 2013-12-12
EA031334B1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
IN2014MN02467A (da)
PH12015501328A1 (en) Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide
PH12015501649A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
MX2012012530A (es) Derivados de n1-sulfonil-5-fluorpirimidinona.
ZA201306719B (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (bace)
MY171831A (en) Novel fused pyrimidine compound or salt thereof
NZ749557A (en) 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
EA201591105A1 (ru) ПИРИМИДО[4,5-b]ХИНОЛИН-4,5-(3H,10H)-ДИОНЫ В КАЧЕСТВЕ СУПРЕССОРОВ НОНСЕНС МУТАЦИЙ
NZ701933A (en) Phenoxyethyl piperidine compounds
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
PH12015502409A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
MX346678B (es) Sales de arginina utiles inmunologicamente.
MX2013015436A (es) Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
GEP20146183B (en) Process for preparation of l-arginine salt of perindopril
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
CR20140545A (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino [1,2-a]indol-1-ona
MY164134A (en) Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
MX358151B (es) Derivado de sitaxentan.
IN2013MU02612A (da)
UA64492U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-(2'-BROMO-3'-PHENYL)ALLYLIDENEHYDRAZINOXANTHINE EXHIBITING DIURETIC ACTION